Clinical trial NCT06742164: Role of Ivabradine for Heart Rate Control in Management of Patients With Sepsis and Septic Shock
Official title: Role of Ivabradine for Heart Rate Control in Management of Patients With Sepsis and Septic Shock
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Heart Rhythm Disorder
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2024-12-19
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Tachycardia is associated with excess mortality during septic shock. This may be related to the increase in cardiac metabolic demand, impaired cardiac diastolic function and less effect of administered exogenous catecholamines.

In this study, we evaluate the effect of enteral Ivabradine on outcome of septic patients regarding need for vasopressor therapy, mechanical ventilation, renal replacement therapy, length of ICU stay and in-hospital mortality.

Detailed description: All patients will be subjected to:

1. Thorough history taking:

   * Demographic data: age, sex and residence.
   * Clinical presentation (fever, hypotension , tachycardia , tachypnea and anuria) .
   * Family history of immunodeficiency disease
   * History of recurrent
2. Clinical examination:

   * Vital signs: heart rate (HR) , blood pressure (BP), and temperature.
   * Abdominal examination .
   * Detect septic focus .
   * Urine out put .
   * Follow up until discharge from ICU.
3. Laboratory investigations:

All patient will be screened with :

* Kidney function test .
* Liver function test.
* Total leukocyticcount was assessed immediately after admission to ICU and then every other day
* C-reactive protien was assessed immediately after admission to ICU and then every other day
* Broad-spectrum antibiotic and then according to cultures and sensitivity.
* Radiological investigation .
* Abdominal ultrasound.
* ECG.
* Echocardiography.

Study tools and procedures:

Epidemiological, demographic, clinical, laboratory, treatment, and outcome data will be obtained from medical records using a standardized data collection form.

Data will be obtained by Randomized controlled clinical trial (RCT) of medical records after, the study methodology reviewed and approved by the Research Review Board of Alhelal hospital (Intensive care unit), Faculty of medicine, Ain Shams University hospitals (Intensive care unit) .

The point of enrolment after initial haemodynamic stabilisation was taken as time 0. The following data sets were recorded at the specified time intervals.

An arterial line and central venous catheter were inserted in all patients for invasive blood pressure and central venous pressure monitoring. The point of enrolment after initial haemodynamic stabilisation was taken as time 0.

If the heart rate was less than 70 beats /min. the dose was omitted. The initial mangement of patients with sepsis and septic shock is summarised on three pillars of therapy.

Stabilization of haemodynamics with target mean arterial blood pressure at 65 mmHg for most patients, begain to rapidly administer 30ml/kg balanced crystalloid within 3 hours for hypotension or lactate ≥ 4mmol/L , Apply vasopressor if hypotensive during or after fluid resuscitation (The vasopressor of choice in septic shock is noradrenaline) , Hydrocortisone 100-200 mg/day is added In patients with refractory hypotension Obtain blood cultures before administration antibiotics. Control source of sepsis. Patients in group (A)were administered 5 mg ivabradine ( orally or crushed and injected through the enteral feeding tube every 12 hours.Heart rate was assessed prior to each dose.

Group (B): Patients didn't receive Ivabradine .

Eligibility criteria: Inclusion Criteria:

* Patients with proven or suspected site of infection.
* Patients sepsis (acute organ dysfunction secondary to documented or suspected infection)
* Patients with septic shock (defined as hypotension unresponsive to fluid resuscitation and requiring vasopressor treatment to maintain adequate blood pressure) for at least 6 hours and less than 24 hours.
* Patients with sinus rhythm with heart rate ≥ 95 bpm at time of randomization. Informed consent obtained in accordance with local regulations.

Exclusion Criteria:

* Cardiac arrhythmia, conduction disorder, sinus syndrome ("sick sinus syndrome"), atrial fibrillation and heart block.
* Cardiogenic shock or acute heart failure, without proven or suspected infection.
* Acute coronary syndrome.
* Refractory shock with systolic arterial pressure \<90 mm Hg despite the use of high doses of vasopressors.
* Co-treatment with drugs inducing bradycardia.
* Patients with pacemakers.
* Known pregnancy, breast-feeding, women with of childbearing potential will be tested for pregnancy and excluded if pregnant.
* Known allergy to Ivabradine
* Severe renal failure (creatinine clearance \<15 ml/min) or hepatic failure (prothrombin time \<20%)
* Tachycardia due to hyperthyroidism, pheochromocytoma or severe anemia (\<7 g/dl)
* Enteral feeding impossible.

Primary outcomes:
measure: the percentage of patients with heart rate reduction of at least 10 beats/min
timeFrame: after 72 hours of treatment
Secondary outcomes:
measure: Mean heart rate
timeFrame: 72 hours of treatment
measure: Mean arterial blood pressure
timeFrame: 72 hours of treatment
measure: percentage of patients needed vasopressor
timeFrame: 72 hours of treatment
Other outcomes:
Locations:
Study officials:
References: